An international serum standard for application in assays to detect human complement activation products

被引:165
作者
Bergseth, Grethe [1 ]
Ludviksen, Judith K. [1 ]
Kirschfink, Michael [2 ]
Giclas, Patricia C. [3 ]
Nilsson, Bo [4 ]
Mollnes, Tom E. [5 ,6 ,7 ]
机构
[1] Nordland Hosp Bodo, Res Lab, Bodo, Norway
[2] Heidelberg Univ, Inst Immunol, D-69115 Heidelberg, Germany
[3] Natl Jewish Heath, Dept Pediat, Allergy & Immunol, Denver, CO USA
[4] Univ Uppsala Hosp, Dept Clin Immunol & Transfus Med, Rudbeck Lab, S-75185 Uppsala, Sweden
[5] Oslo Univ Hosp Rikshosp, Inst Immunol, Oslo, Norway
[6] Univ Oslo, N-0316 Oslo, Norway
[7] Nordland Hosp, Res Lab, NO-8092 Bodo, Norway
关键词
Complement; Assay; Activation products; Standard; LINKED-IMMUNOSORBENT-ASSAY; 5TH COMPONENT; QUANTIFICATION; NEOEPITOPE; PLASMA; C5A; GENERATION; BLOOD;
D O I
10.1016/j.molimm.2013.05.221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The importance of the complement system in clinical medicine has become evident during the last decades and complement therapeutics has now reached the clinic. Thus, there is an increased interest in and need for assays to evaluate complement activity and dysfunction. Pathologically increased complement activation can indirectly be evaluated by quantification of complement components, but in order to exactly measure such activation, assays for quantification of products formed during activation are required. Progress in this field is hampered by lack of standardization. Therefore, members of the International Complement Standardization Committee, a joint initiative of the International Complement Society and the International Union of Immunological Societies (IUIS), prepared a defined standard for application in assays for complement activation products. We here report on the production and properties of this International Complement Standard #2 (ICS#2). ICS#2 was made from a pool of sera from healthy blood donors (ICS#1) that was activated with a combination of heat-aggregated IgG and zymosan, and subsequently stabilized by adding EDTA and nafamostat mesylate. The protocol was optimized to make the standard applicable in the following activation product assays: C1rs-C1-inhibitor complexes, C4a, C4bc, C4d, Bb, C3bBbP, C3a, C3bc, C3dg, C5a and the soluble terminal C5b-9 complement complex (SC5b-9, TCC). ICS#2 was defined as containing 1000 complement activation units (CAU)/mL for all activation products measured. All activation products were stable after 10 times thawing and freezing and most of the activation products were stable during storage at 4 degrees C for up to 21 days. ICS#2 was produced large-scale and is considered a valuable tool for standardization, calibration and reference control for complement activation assays, providing the necessary prerequisite for quality assessments between complement laboratories. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:232 / 239
页数:8
相关论文
共 19 条
  • [1] MEASUREMENT OF THE COMPLEMENT C-3 BREAKDOWN PRODUCT C3D BY ROCKET IMMUNOELECTROPHORESIS
    BOURKE, BE
    MOSS, IK
    MAINI, RN
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 48 (01) : 97 - 108
  • [2] FLUID PHASE GENERATION OF TERMINAL COMPLEMENT COMPLEX AS A NOVEL INDEX OF BIOINCOMPATIBILITY
    DEPPISCH, R
    SCHMITT, V
    BOMMER, J
    HANSCH, GM
    RITZ, E
    RAUTERBERG, EW
    [J]. KIDNEY INTERNATIONAL, 1990, 37 (02) : 696 - 706
  • [3] A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s
    Fure, H
    Nielsen, EW
    Hack, CE
    Mollnes, TE
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1997, 46 (06) : 553 - 557
  • [4] QUANTIFICATION IN ENZYME-LINKED IMMUNOSORBENT-ASSAY OF A C-3 NEOEPITOPE EXPRESSED ON ACTIVATED HUMAN-COMPLEMENT FACTOR-C3
    GARRED, P
    MOLLNES, TE
    LEA, T
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1988, 27 (03) : 329 - 335
  • [5] Advances in assay of complement function and activation
    Harboe, Morten
    Thorgersen, Ebbe Billmann
    Mollnes, Tom Eirik
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (12) : 976 - 987
  • [6] Generation of C5a in the absence of C3: a new complement activation pathway
    Huber-Lang, Markus
    Sarma, J. Vidya
    Zetoune, Firas S.
    Rittirsch, Daniel
    Neff, Thomas A.
    McGuire, Stephanie R.
    Lambris, John D.
    Warner, Roscoe L.
    Flierl, Michael A.
    Hoesel, Laszlo M.
    Gebhard, Florian
    Younger, John G.
    Drouin, Scott M.
    Wetsel, Rick A.
    Ward, Peter A.
    [J]. NATURE MEDICINE, 2006, 12 (06) : 682 - 687
  • [7] MOLLNES T E, 1985, Complement, V2, P156
  • [8] QUANTIFICATION OF THE TERMINAL COMPLEMENT COMPLEX IN HUMAN-PLASMA BY AN ENZYME-LINKED IMMUNOSORBENT-ASSAY BASED ON MONOCLONAL-ANTIBODIES AGAINST A NEOANTIGEN OF THE COMPLEX
    MOLLNES, TE
    LEA, T
    FROLAND, SS
    HARBOE, M
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1985, 22 (02) : 197 - 202
  • [9] MOLLNES TE, 1993, CLIN EXP IMMUNOL, V91, P295
  • [10] Mollnes TE, 2002, BLOOD, V100, P1869